

**Dr Tan Min-Han** is the founder and CEO of Lucence Diagnostics Pte Ltd. The company's mission is to illuminate the most complex medical diagnoses through relentless innovation and deeper insights. Lucence delivers innovative services to cancer physicians and patients to relieve suffering and improve health.

A world leader in medicine, Dr Tan's research has spanned diverse fields of clinical medicine, human genetics and medical data analytics to regularly rewrite orthodoxy. Trained as a medical oncologist and geneticist, he received his medical degree from the National University of Singapore (NUS) in 1998 with the Brunel Hawes Gold Medal, Nestle Paediatrics Gold Medal, and Lim Boon Keng Medal. He completed medical oncology fellowship training at the National Cancer Centre Singapore, and a PhD for molecular cancer epidemiology. He was awarded the Ambrose Monell and Lee Foundation clinical cancer genetics fellowship at the Genomic Medicine Institute, Cleveland Clinic, Ohio. He was elected Fellow of the Royal College of Physicians Edinburgh in 2015.

Dr. Tan's research interests centre on innovative cancer diagnostics and data analytics. He has contributed over 100 publications, receiving awards for research excellence from ASCO, ESMO and ASEAN. His laboratory is noted for discovering the circulating tumor-endothelial cluster (CTEC) in cancer patients in 2016, representing a second major class of circulating tumor-derived cells and thus overturning a 50 year dogma on cancer clusters (N Engl J Med 1960). Among his contributions to clinical care, he described the lifetime cancer risks for patients with a hereditary breast cancer syndrome (PTEN mutation), developing corresponding adult and paediatric diagnostic criteria and treatment recommendations.

In public service, he is a steering committee member of the I-CONFIRM consortium of the US National Cancer Institute (NCI) and a member of the Drug Advisory Committee, Ministry of Health, Singapore. He is a visiting consultant at the National Cancer Centre Singapore, Tan Tock Seng Hospital, Sengkang General Hospital, Novena Cancer Centre, and Concord International Hospital.